Latest News

  • Life-like “on-a-chip” model of human perfused blood vessels offers new solutions for toxicity testing, drug discovery, and precision medicine
    Neuchâtel, Switzerland, 01 October 2019 – A unique, three-dimensional model of human blood vessels has been demonstrated to accurately assess a key stage in the development of inflammation and vascular disorders such as atherosclerosis. The microvessel-on-a-chip, jointly developed and optimized by Philip Morris International (PMI) and organ-on-a-chip specialists MIMETAS (Leiden, The Netherlands), can be used under flow to measure the attachment of immune cells to the blood vessel wall—an important feature of early onset atherogenesis—as well as gain unique mechanistic insights through analysis of transcriptomic profiles. In addition, the model has been shown to be effective in applications such as the toxicological assessment of consumer products.
  • Virus lasers open up new avenues for monitoring biology
    Virus lasers have the potential to become a once-in-a-generation analytical technology that will have a transformative impact in biological manufacturing, clinical diagnostics, and environmental sensing.
  • Lab Innovations 2019 to showcase advances shaping the laboratories of the future
    Game-changing instrumentation and presentations spanning new regulations to artificial intelligence feature in the UK’s most forward-thinking laboratory event
  • This week in Drug Discovery Today
    As a service from Drug Discovery Today, we are beginning to highlight those papers that have been published as "Articles in Press" either as corrected or uncorrected proofs in the preceding week. We hope that they are of interest to you. The articles are citable via their doi.
  • Pollen could be the key to tackling antibiotic resistance
    Pollen might cause misery to millions with hayfever sniffles every spring and summer, but new research has revealed it could hold the key to saving millions of lives.
view more

Podcasts

view more

Webinars

  • The Promise of Epigenetics in Early Stage Drug Discovery
    Epigenetic targets are exciting to drug discovery scientists because they hold great potential across a wide spectrum of therapeutic areas. The field of epigenetics focuses on the investigation of enzymes that alter gene expression through modification of their target substrates, usually through the addition or removal of methyl or acetyl groups. High-throughput assays to identify agents capable of modifying the action of such enzyme targets has, in the past, proven to be challenging due to the relatively small molecular alterations in addition to the possibility of sequential modifications, leading to multiple end products. As such, high-throughput bioassays that allow the direct, concurrent quantification of multiple modification states are attractive. The RapidFire platform enables high-throughput mass spectrometric analysis of native molecules from in vitro reactions by performing on-line desalting in seconds, as opposed to HPLC, which requires minutes. Moreover, the RapidFire system can be connected to any mass spectrometer providing unparalleled versatility in reaction detection.
  • Integrated Quant / Qual for In-vivo Discovery Bioanalysis using Hybrid Quadrupole-Time-of-Flight Mass Spectrometry
    Ultra high performance liquid chromatography (UHPLC) coupled with orthogonal acceleration hybrid quadrupole-time-of-flight (QqTOF) mass spectrometry is an emerging technique offering new strategies for the efficient screening of new chemical entities (NCE) and related molecules at the early discovery stage within the pharmaceutical industry.
  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
view more

Features

view more

Downloads

view more

25 Hottest Articles

view more